Redistribution of thorotrast into a liver allograft several years following transplantation: a case report

Krasinskas, Alyssa M.; Minda, Justina M.; Saul, Scott H.; Shaked, Abraham; Furth, Emma E.

doi:10.1038/modpathol.3800008

Cited by 18 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most serious misevaluations in the history of CA happened with Thorotrast®, a suspension of thorium dioxide ( 232 ThO 2 ) that was used worldwide between the 1930s and 1950s for cerebral angiography, hepatosplenography, paranasal sinus imaging, and peripheral angiography. It had a high opacity and no acute toxicity, although after years, it was shown to be retained by the RES. With a biological half‐life of several hundred years, it led to lifetime exposure to low doses of alpha radiation, inducing malignancies such as hepatocellular carcinoma, cholangiocarcinoma, and hemangiosarcoma as well as hematopoietic malignancies, leading to its withdrawal…”

Section: General Demands On Camentioning

confidence: 99%

Status and trends in the development of clinical diagnostic agents

Opacic

Paefgen

Lammers

et al. 2016

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Contrast agents (CA) are routinely used in clinical practice to improve the diagnosis of diseases and to monitor therapy response. The majority of CA comprises small molecules accumulating at pathological sites due to vascular abnormalities, such as changes in perfusion and permeability. For many diseases, high diagnostic accuracy can be achieved with contrast-enhanced imaging. This means that new CA will only succeed in translation if they either show superior performance with respect to diagnostic accuracy, safety and cost, support a new imaging modality, or are directly linked to the refinement of therapy, e.g., as a companion diagnostic. Unfortunately, these basic demands are often not carefully considered by the scientific community, leading to concepts with low chances of clinical translation. Thus, it is not surprising that, despite steadily increasing numbers of publications, there is quite the opposite trend when it comes to the clinical approval of new diagnostics. As a matter of fact, except for PET tracers, in the last decade, only a handful of CA received FDA or EMA approval. Furthermore, several approved products were discontinued by the manufacturers because of low market potential, a competitive own product, suboptimal clinical performance, or safety concerns. This review article discusses the current status of approved diagnostic probes for clinical imaging modalities, with a focus on new trends in CA development. In this context, molecularly targeted diagnostics or probes for emerging fields, such as image-guided surgery, nanomedicine, or theranostics, will be introduced and discussed with regard to their clinical translation. WIREs Nanomed Nanobiotechnol 2017, 9:e1441. doi: 10.1002/wnan.1441 For further resources related to this article, please visit the WIREs website.

show abstract

Section: General Demands On Camentioning

confidence: 99%

Status and trends in the development of clinical diagnostic agents

Opacic

Paefgen

Lammers

et al. 2016

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…That Thorotrast phagocytosed by macrophages can locate from extrahepatic compartments to the liver has also been demonstrated in a patient with a liver allograft who had received intraarticular Thorotrast 36 years prior to transplantation. A liver graft biopsy performed 10 years posttransplant showed typical Thorotrast particles in macrophages in portal tracts and around central veins (Krasinskas et al 2004).…”

Section: Thorotrast Deposition and Turnover In The Livermentioning

confidence: 99%

“…In addition to tumor-like lesions, node-shaped histiocytic proliferations with characteristic eosinophilic substance around Thorotrast deposits have also been described (Levy 1960). On the other hand, septal fibrosis and cirrhosis of the liver may ensue (Aizawa et al 1960;Momose et al 1966;Ueda et al 1966;Takagi and Hasebe 1972;Vanhaecke et al 1979;Mori et al 1983;Morant and R€ uttner 1987;Marti Vicente et al 1993;Sharp 2002), with an often coarsely nodular pattern (Krasinskas et al 2004). In regard to cirrhosis, a 20-fold increase in risk has been calculated (Kato and Kido 1987).…”

Section: Fibrotic Changes Induced By Thorotrast and "Thorotrastomas"mentioning

confidence: 99%

Hepatic and Perihepatic Involvement in Pneumokonioses and Other Mineral-Induced Diseases

Zimmermann¹

2016

Tumors and Tumor-Like Lesions of the Hepatobiliary Tract

View full text Add to dashboard Cite

“…Nach der Injektion von durchschnittlich 25 ml Thorotrast, das 5 g Thorium mit einer Aktivität von 0,5 μCi bzw. 18,5 kBq 232-Th und additiv weiterer Zerfallsprodukte enthielt [13] , in die Arteria carotis konnten besonders kontrastreiche Bilder des Gehirns (arterielle Enzephalographie) gewonnen werden. (Abb.…”

unclassified

Vor 90 Jahren – Die erste erfolgreiche zerebrale Arteriographie mit Thorotrast

Busch

2022

Zeitschrift für Medizinische Physik

View full text Add to dashboard Cite

Redistribution of thorotrast into a liver allograft several years following transplantation: a case report

Cited by 18 publications

References 11 publications

Status and trends in the development of clinical diagnostic agents

Status and trends in the development of clinical diagnostic agents

Hepatic and Perihepatic Involvement in Pneumokonioses and Other Mineral-Induced Diseases

Vor 90 Jahren – Die erste erfolgreiche zerebrale Arteriographie mit Thorotrast

Contact Info

Product

Resources

About